Search
Mesothelioma Treatment Options Asbestos Exposure News Veterans And Mesothelioma About ELSS FREE Case Evaluation Top Mesothelioma Doctors

Borys Mychalczak, M.D.
Dr. Borys Mychalczak is Chief of Radiation Oncology at the Memorial Sloan-Kettering regional care facility in Sleepy Hollow, New York.

Lary Robinson, M.D.
Dr. Lary A. Robinson is the Director of Cardiovascular and Thoracic Surgery at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida where he evaluates and treats mesothelioma.

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here.

Free Mesothelioma Information Packet

Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.

Yes   No

A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.

PURPOSE: Patients with malignant mesothelioma or adenocarcinoma of the lung often present with respiratory complications associated with a malignant pleural effusion. Distinguishing between these malignancies is frequently problematic, as many of the clinical, cytologic, and histologic features of the diseases overlap. Following cytologic analysis of pleural effusions, subsequent confirmatory tissue biopsies involve increased patient morbidity and expense. We have therefore designed a gene expression-based test to classify the primary tumor causing a malignant pleural effusion, using cells collected from the effusion itself. EXPERIMENTAL DESIGN: We have used microarray data for 190 lung adenocarcinomas and 33 malignant mesotheliomas to identify genes differentially expressed between the two diseases. Genes expressed in normal mesothelial cells were removed, allowing the development of a PCR-based test to measure the expression of genes that discriminate between mesothelioma and lung adenocarcinoma from cytology specimens. RESULTS: Applying an real-time PCR-based assay involving 17 genes to 13 independent samples from biopsy-proven malignant mesothelioma and lung adenocarcinomas resulted in the correct identification of all samples. CONCLUSIONS: We have developed a test that is able to distinguish between lung adenocarcinoma and mesothelioma in cells collected from pleural effusions.

Source

PMID: 16951230 [PubMed - in process]
Click here to order or save article

If you have any questions regarding treatment options or your legal rights, please contact us.